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ABSTRACT 
Background: Pulmonary embolism (PE) is potentially lethal acutely and prone to recur. After 
anticoagulant therapy discontinuation, the rate of recurrences increases with time and therefore 
decide when and how to stop secondary prophylaxis may be difficult in several patients. 
Objective: to investigate the incidence of mortality and recurrence of PE and the time course of 
these events during a 5 year-follow-up in patients who discontinue and in those who continue 
secondary prophylaxis only according to 2001 ACCP Guide-lines. Secondary purposes were to 
evaluate the risk factors for recurrences and mortality of PE in patients who continue and in those 
who discontinue therapy and the incidence of bleeding in the former group of patients. 
Design and methods: we evaluated consecutive patients with acute PE enrolled in a single 
University centre during a 5 year-period (2001-2005), and followed for 5 further years (2006-2011) 
after the decision to continue or stop anticoagulant treatment on the basis of 2001 ACCP Guide-
lines.  
Results: we considered 471 patients with PE that were followed for 5 year follow-up period. 
Among them, 361 (76.6 %) continued anticoagulant therapy, the remaining 110 (23.4 %) patients 
stopped it. Among all patients, 263 (55.8%) completed the 5 year-follow-up period while 122 
(25.9%) patients died before completing it and 86 (18.3%) were lost to follow-up. Patients who 
continued anticoagulant therapy experienced 34 (72.3%) recurrences (incidence recurrence rate 2.58 
events for 100 person-years), while patients who discontinued therapy developed 13 (27.7 %) 
recurrences (incidence recurrence rate 2.92 events for 100 person-years). In the group of patients 
who continued anticoagulant therapy, 109 (89.3 %) deaths (mortality rate 8 events for 100 person-
years) occurred, while in the group who discontinued it 13 (10.7 %) deaths (mortality rate 2.84 
events for 100 person-years) occurred; the difference between the two groups was statistically 
significant (RR 2.81, 95% CI 1.58-5.46). The group of patients who continued anticoagulant 
therapy experienced 13 fatal recurrences (incidence recurrence rate 0.95 events for 100 person-
years) while patients who discontinued it had 4 fatal recurrences (incidence recurrence rate 0.8 
events for 100 person-years). Among patients who continued anticoagulant therapy, those with 
unprovoked or recurrent PE show more than 3 times grater probability of dying for fatal recurrence 
than those who continued treatment since affected by uncontrolled cancer or disabling chronic 
illness (RR 3.60, 95% CI 001-1.84). Recurrence was significantly associated with age greater than 
61 years and with the presence of DVT at the diagnosis of PE. Conditions independently associated 
with all-cause mortality, were age greater than 70 years, presence of cancer, and continuation of 
anticoagulant therapy. Fatal recurrences, were significantly  associated with age greater than 78 
years. 
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Conclusion: our findings suggest that, according to Guide-lines, most patients (80%) should be 
anticoagulated for long period of time; that prolonging anticoagulation markedly reduce the risk for 
fatal recurrence in all patients and, mostly, in those with unprovoked PE, while it does not decrease 
total recurrences or all-cause mortality. This, indeed, is influenced greatly by the presence of 
cancer, both in patients who continue and in those who stop anticoagulant prophylaxis. Whether or 
not the strategy of adhering to Guide-lines is correct remains not demonstrated. 
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INTRODUCTION 
 
Pulmonary embolism (PE) is potentially lethal acutely and prone to recur during the 
following days, months, years [1-2]. After anticoagulant therapy discontinuation, the rate of 
recurrences increases with time but the prolongation of anticoagulant prophylaxis beyond 6-12 
months has not shown useful to prevent recurrencies and mortality [3-7]. Nevertheless, to decide 
when and how to stop secondary prophylaxis may be difficult in several patients. Unprovoked 
nature of VTE, recurrence of VTE, presence of cancer and chemo-radiotherapy, persistence of 
residual thrombotic material in pulmonary circulation, presence of thrombophylic abnormalities, 
presence of chronic medical illnesses have all be considered as potential causes for increased 
recurrences or mortality after discontinuation of prophylaxis [8-12]. However, some of the 
aforementioned causes may play a different role in patients who must continue secondary 
anticoagulant prophylaxis beyond 3-6 months and in those who may stop it. The decision for 
continuing the prophylaxis beyond the commonly suggested period is often left to the single 
physician because the available guide-lines are felt as non definitive on this topic; indeed, a 
systematic long term survey of main adverse events in patients who continue or stop anticoagulant 
therapy was not available insofar.  
The main purpose of the present study was to investigate the incidence of mortality and 
recurrence of PE and the time course of these events during a 5 year-follow-up in patients who 
discontinue and in those who continue secondary prophylaxis. Secondary purposes were to 
evaluate: the risk factors for recurrences and mortality of PE in both groups and the incidence of 
bleeding  in the group of patients who continued anticoagulant therapy. 
Accordingly, we evaluated consecutive patients with acute PE enrolled in a single 
University centre during a 5 year-period (2001-2005), treated with anticoagulant terapy for 1 year 
and then followed for 5 further years (2002-2006) after the decision to continue or stop 
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anticoagulant treatment. To be as consistent as possible and, contemporarily, to remain as close to 
real life as possible, patients did continue or stop anticoagulant therapy only according to 2001 
ACCP Guide-lines [13]. 
 
MATERIALS AND METHODS 
 
The study included all consecutive patients who had a diagnosis of  PE performed by CT 
pulmonary angiography or by a positive lung scintigraphy in conjunction with high clinical 
probability of PE [14], between 2001 and 2005. Patients were referred to the Centre for the 
Diagnosis and Treatment of PE of the Pulmonary Unit of the University of Pisa which is the referral 
centre for the population of Pisa and surrounds (about 120,000 inhabitants). In the pulmonary Unit, 
patients had the appropriate treatment with fibrynolitics, LMWH or UFH for 7 days and, 
subsequently, underwent oral anticoagulants (or subcutaneous LMWH in patients with uncontrolled 
neoplasm); here they also had a baseline perfusion lung scintigraphy within 24 hours from the 
diagnosis made by CT scan, in order to have a basal pattern to compare with during the follow-up in 
case of suspected recurrence. At the admission, patients were assessed for demographic data, 
comorbid conditions, predisposing factors for venous thromboembolism, symptoms and signs. 
Patients were classified as having secondary PE if they had had a recent (less than 3 months) major 
surgical procedure, leg trauma or fracture or they had been bedridden for more than 1 week, or they 
were pregnant, had given birth within the previous 3 months, or took estrogens, or they had history 
of lower deep vein thrombosis (DVT), or any prior episode of PE, or active cancer. In detail, we 
defined cancer as active if it had been recently diagnosed or if it was still treated with chemotherapy 
or radiotherapy. In case of patients with more than one risk factor we consider the more relevant as 
the main cause of PE. All patients without the above mentioned risk factors were regarded as 
having an unprovoked episode of PE.  
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Study outcome 
The inclusion into the study started one year after hospital dismission when patients 
continued or stopped anticoagulants only on the basis of the 2001 ACCP Guide-lines [13]. In 
practice patients who had unprovoked PE, or had had previous episodes of VTE, or recurrence in 
the first year of treatment, or were affected by active cancer, or atrial fibrillation, or chronic disease 
leading to immobilisation continued anticoagulant therapy  and patients were regularly followed in 
the hospital anticoagulation clinic. On the contrary, patients with PE secondary to known reversible 
risk factors discontinued therapy. Then, patients were followed for 5 years until the completion of 
the observation period or death or until they were lost to follow-up. Mortality Register of the 
Tuscany Region was consulted for mortality, both for all causes and for specific death. In all 
patients who died, the cause of death was reported. Death was considered as due to PE if it was 
confirmed by autopsy, if it was anteceded by non-fatal manifestations of recurrent 
thromboembolism, or if death occurred suddenly and no alternative explanations could be found. 
Suspected recurrence was confirmed by objective test; the criteria for the diagnosis of recurrence of 
pulmonary embolism were one or more new segmental defects revealed by lung scan. Sudden, 
otherwise unexplained death was also considered a recurrence of pulmonary embolism. The criteria 
for the diagnosis of  recurrent deep venous thrombosis were abnormal results on compression 
ultrasonography (proximal veins) in the contralateral leg or, in the ipsilateral leg, a newly 
noncompressible venous segment or an increase of 4 mm or more in the diameter of the thrombus 
(proximal veins) on ultrasonography. The diagnosis of recurrences was performed by a team of 
physicians particularly expert in both pulmonary nuclear medicine and vascular medicine. 
Bleedings were sought in all patients at the time of ambulatory visits. Bleedings where categorized 
as major and minor. We classified as major the following: fatal (death due to haemorrhage), 
intracranial (documented by imaging), intra-abdominal, required surgery or angiographic 
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intervention and if bleeding led to haemoglobin reduction of 2g/dL or more and/or needed 
transfusion. Minor bleedings were considered all those not fulfilling criteria for major bleedings. 
The study was a single-centre, prospective, observational cohort study performed in an 
academic teaching hospital and was approved by the insitutional review board for human studies of 
the University of Pisa. 
 
Statistical Analysis 
Continuous variables were expressed as mean  1 SD and categorical variables as 
percentages. The duration of follow-up was expressed in years. We considered clinical outcomes 
that occurred during follow-up from the time of recruitment until death or the end of patient follow-
up. The primary end points were the occurrence of all-cause and specific mortality and VTE 
recurrence. To standardize for different lengths of follow-up in the cohort, we used the annual rate 
for recurrent VTE, death for all causes and for fatal PE (the number of events per 100 person-years 
of follow-up). The Kaplan–Meier method was used to determine the time course of events. 
The secondary endpoints were to investigate the predictors of events that were identified by 
univariate and multivariate analysis performed using the Cox proportional hazards regression 
model. Categorical variables were included into the model as dummy variables. Parameters that 
were significantly associated with the risk of death for all causes and for fatal recurrence and with 
the risk of VTE recurrence on univariate analysis were entered in a multivariate Cox proportional 
hazard model to identified features indipendently associated with events. In detail, we sought to 
estimate the strenght of any association between mortality for all causes, mortality for fatal 
recurrence and VTE recurrence and the following parameters: age, gender, presence of associated 
DVT, previous episodes of VTE, presence of cardiovascular comorbidities and of active cancer, 
unprovoked PE. All statistical tests were two-tailed; a p <0.05 was considered as significant. 
Statistical analysis was performed with commercially and free available software (SPSS 16.0, SPSS 
Inc., Chicago, Illinois, USA). 
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RESULTS 
 
Five hundred and eighty five patients had a diagnosis of pulmonary embolism between 2001 
and 2005. The diagnosis of PE was performed by using CT pulmonary angiography in 526 (90%) 
patients; in the remaining 59 (10%) patients the diagnosis was made on the basis of a positive lung 
scintigraphy in conjunction with a high clinical probability of PE. 
Mean age was 68.7 years with a prevalence of subjects of female sex (56.4 %). Among the 
risk factors, surgical procedures (38.8 %) and active cancer (36.1 %) were the most represented. 
Lung (55, 47.0 %) and gastrointestinal (45, 38.5 %) cancer were the most frequent neoplasms, 
followed by renal (23, 19.7 %), breast (13, 11.1 %), gynecological (12, 10.3 %), hematologic (12, 
10.3 %), brain (6, 5.1 %), skin (2, 1.7 %), thyroid (1, 0.9 %) cancer. Among 169 patients with active 
cancer, 93 (55 %) had metastatic disease and 39 (41.9 %) were being treated with chemotherapy or 
radiotherapy. Cardiovascular disease (363 cases, 62.1 %) and active cancer (169 cases, 28.9 %) 
were the most frequent comorbidities.  
Among all 585 patients, 170 (29.1 %) had associated DVT, 36 (6.2%) reported a previous 
episode of  VTE. Among them, 25 (69.4 %) had a previous PE, 3 (8.3 %) DVT and PE and 8 (22.2 
%) isolated DVT. In 261 patients (44.6%) no identified risk factor was found and PE was classified 
as unprovoked. In 324 (55.4%) patients recent major surgical procedure (126, 38.8%), active cancer 
(117, 36.1%), previous VTE (30, 9.3%), immobilization for more than 1 week (22, 6.8%), bone 
fracture (17, 5.2%), estrogen use (12, 3.7%), were demonstrated risk factors and PE was classified 
as secondary. 
The study population consisted of 471 patients (table I) who were followed for a 5-year- 
follow-up period. They were part of the entire patients population diagnosed during 5 years (585 
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patients); of them, 114 (19.5%) were lost during the first year after diagnosis (83, 72.8% died and 
31, 27.2% did not return to control). 
 
Table I.  Baseline Characteristics of patients  N 471 ( 100% ) 
Age* 67.9 ( 17-95 ) 
Age<61 115 ( 24.4 ) 
61 Age≤70 117 ( 24.8 ) 
71≤Age≤78 122 ( 25.9 ) 
>78 Age 117 ( 24.8 ) 
Male gender 212 ( 45 ) 
PE+ DVT  151 ( 32.1 ) 
Unprovoked PE 225 ( 47.8 ) 
Previous VTE 31 ( 6.6 ) 
Comorbidities  
Cardiovascular disease 290 ( 61.6 ) 
Active Cancer  104 ( 22.1 ) 
Respiratory disease 88 ( 18.7 ) 
Diabetes 79 ( 16.8 ) 
Obesity 18 (3.8 ) 
Previous ischemic stroke 13 ( 2.8 ) 
* Age is presented as mean ( range )  
Risk factors ** N 246 (100%) 
  
Surgery 110 ( 44.7 ) 
Active cancer 65 ( 26.4 ) 
Previous VTE  26 ( 10.6 ) 
Immobilization >7 days 18 ( 7.3 ) 
Bone fracture 15 ( 6.1 ) 
Estrogen use 12 ( 4.9 ) 
**Risk factors are reffered to 246 patients with secondary PE  
 
 
 
 
Among 471 patients, 361 (76.6 %) continued anticoagulant therapy because of unprovoked 
PE (225, 62.3%), previous episodes of VTE (27, 7.5%), first year recurrence (4, 1.1%), presence of 
active cancer (81, 22.4%), atrial fibrillation (11, 3%), disabiling chronic disease (13, 3.6%). The 
remaining 110 (23.4 %) secondary patients discontinued anticoagulant therapy. The clinical 
characteristics of both groups of patients are represented in table II.  
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Table II.  Baseline Characteristics of patients  
 Patients who continued 
anticoagulant therapy 
Patients who discontinued 
anticoagulant therapy 
   
N 361 (100%) 
 
N 110 (100%) 
Age * 
  
69.9 ( 17-95) 
 
61.4 (24-89) 
Age<61  69 (19.1) 46 (41.8) 
61 Age≤70  91 (25.2) 26 (23.6) 
71≤Age≤78  99 (27.4) 23 (20.9) 
>78 Age  102 (28.3) 15 (13.6) 
Male gender  175 (48.5) 37 (33.6%) 
PE+ DVT   114 (31.6%) 37 (33.6%) 
Unprovoked PE  225 (62.3%) - 
Previous VTE  31 (8.6%) - 
*Age is presented as mean (range) 
 
Comorbidities 
   
Cardiovascular disease  237 (65.6) 53 (48.2) 
Active Cancer   85 (23.5) 19 (17.3) 
Respiratory disease  74 (20.5) 14 (12.7) 
Diabetes  69 (19.1) 10 (9.1) 
Obesity  14 (3.9) 4 (3.6) 
Previous ischemic stroke  12 (3.3) 1 (0.9) 
Risk factors **   
N 136 (100%) 
 
N 110 (110%) 
Surgery  
 
9 (6.6) 
63 (57.3) 
Active cancer  85 (62.5) 19 (17.3) 
Previous VTE   26 (19.1) - 
Immobilization >7 days  16 (11.8) 11 (10) 
Bone fracture  - 5 (4.5) 
Estrogen use 
  
- 12 (10.9) 
**Risk factors are referred to patients with secondary PE    
 
 
Among the original 471 patients, 263 (55.8%) completed the 5 years-follow-up period while 
122 (25.9%) patients died before completing it and 86 (18.3%) were lost to follow-up because they 
did not come back for clinical controls. 
 
 
Risk of Recurrence 
    
  During the 5-years-follow-up, we recorded 47 recurrences of VTE among all patients; of 
them, 17 occurred in the 1st year (cumulative incidence 3.7%), 3 in the 2nd year (cumulative 
incidence 4.4%), 7 in the 3rd year (cumulative incidence 6.3%), 9 in 4th year (cumulative incidence 
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9.1%) and 11 in 5th year (cumulative incidence 12.9%). Recurrences occurred in 37 (78.7 %) cases 
as isolated PE, in 8 (17 %) cases as PE associated with DVT and in 2 (4.3 %) as isolated DVT.  
  Patients who continued anticoagulant therapy experienced 34 (9.4%) recurrences (incidence 
recurrence rate 2.58 events for 100 person-years of follow-up), while patients who discontinued 
therapy developed 13 (11.8%) recurrences (incidence recurrence rate 2.92 events for 100 person-
years of follow-up). The difference on recurrent VTE between the two groups of patients was not 
statistically significant (RR 0.88, 95% CI 0.45-1.82). 
 
All – cause mortality 
During the study period we recorded 122 deaths in all patients;  of them, 34 occurred in the 
1st year (cumulative mortality 7.2%), 21 in the 2nd year (cumulative mortality 12%), 26 in the 3rd 
year (cumulative mortality 18.4%), 28 in the 4th year (cumulative mortality 25.7%) and 13 in the 
5th year (cumulative mortality 29.1%). (Figure 1). The cause of death in all patients were active 
cancer in 51 (41.8%) cases, cardiovascular disease in 34 (27.9%) cases, fatal recurrence of PE in 17 
(13.9%) cases, liver insufficiency in 5 (4.1%) cases, respiratory disease in 5 (4.1%) cases, 
neurological disease in 4 (3.3%) cases, major bleeding in 3 (2.5%) cases and renal insufficiency in 3 
(2.5%) cases (Table II). In the group of patients who continued anticoagulant therapy, 109 (30.2%) 
deaths (incidence rate 8 events for 100 person-years of follow-up) occurred, while in the group who 
discontinued therapy 13 (11.8%) deaths (incidence rate 2.84 events for 100 person-years of follow-
up) occurred. The difference between the two groups of patients in the occurrence of death was 
statistically significant (RR 2.81, 95% CI 1.58-5.46). Figure 1. 
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Figure 1. Occurrence of all-cause death in patients who continued treatment (treated) and in 
patients who stopped it (untreated). Kaplan-Meier  analysis. (The numbers represent patients at risk 
for all-cause death). 
 
 
 
Table II. Causes of death in 122 patients. 
 
 Deaths in patients who continued 
anticoagulant therapy 
 
N 109 (30.2%) 
Deaths in patients who discontinued 
anticoagulant therapy 
 
N 13 (11.8%) 
Active cancer 46 (12.7) 5 (4.5) 
Cardiovascular disease 31 (8.6) 3 (2.7) 
Fatal recurrence of PE 13 (3.6) 4 (3.6) 
Liver insufficiency 5 (1.4) - 
Respiratory disease 4 (1.1) 1 (0.9) 
Neurological disease 4 (1.1) - 
Major bleeding 3 (0.8) - 
Renal insufficiency 3 (0.8) - 
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Mortality for fatal recurrent PE 
 
Among 47 recurrences, 17 (36.2%) were fatal (incidence recurrence rate 0.93 events for 100 
person-years of follow-up). Fatal recurrent events, occurred in 5 cases in the 1st year (cumulative 
incidence 1.0%), in 1 case in the 2nd year (cumulative incidence 1.3%), in 4 cases in the 3rd year 
(cumulative incidence 2.1%), in 4 cases in the 4th year (cumulative incidence 4.0%) and 3 cases in 
the 5th year (cumulative incidence 4.7%). The group of patients who continued anticoagulant 
therapy experienced 13 fatal recurrences (incidence recurrence rate 0.95 events for 100 person-
years of follow-up) while patients who discontinued treatment 4 (incidence recurrence rate 0.8 
events for 100 person-years of follow-up). The difference between the two groups of patients on 
fatal recurrences was not statistically significant (RR 1.09, 95% CI 0.34-4.59) (Figure 2). 
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Figure 2. Occurrence of fatal recurrence in patients who continued treatment (treated) 
and in patients who stopped it (untreated). Kaplan-Meier analysis. (The numbers 
represent patients at risk for fatal recurrence). 
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Additional observations  
 
In order to evaluate the role of unprovoked PE and of previous episode of VTE in 
determining mortality and new recurrence, we divided patients who continued prophylaxis in two 
groups: those with unprovoked PE or with previous VTE and those with active cancer and chronic 
medical illness. Among the fisrt group (256 patients), we recorded 59 deaths for all causes 
(incidence rate 0.48 events for 100 person-years of follow-up), 12 fatal recurrence of PE (incidence 
fatal recurrence rate 0.1 events for 100 person-years of follow-up), and 28 recurrences ((incidence 
recurrence rate 0.24 events for 100 person-years of follow-up), while in the second group (94 
patients) we recorded 48 deaths for all causes (incidence rate 1.33 events for 100 person-years of 
follow-up), only 1 fatal recurrence of PE (incidence fatal recurrence rate 0.03 events for 100 
person-years of follow-up) and 5 recurrences (incidence recurrence rate 0.14 events for 100 person-
years of follow-up in the second). The difference between the two groups of patients in the 
occurrence of death was statistically significant (RR 2.75 95% CI 1.84-4.09) (Figure 3). The 
difference between the two groups in the occurrence of fatal recurrences and recurrences of PE was 
not statistically significant (RR 3.60, 95% CI 0.01-1.84 and RR 1.72, 95% CI 0.17-1.52 
respectively), but patients with unprovoked PE or previous VTE were much more likely to develop 
fatal recurrences of VTE than those with cancer or disabiling chronic disease. 
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Figure 3. Occurrence of all-cause death in patients who continued prophylaxis with 
unprovoked PE or previous VTE and in patients who continued prophylaxis with cancer or 
disabling chronic disease. Kaplan-Meier analysis. (The numbers represent patients at risk for all-cause 
death). 
 
 
 
Risk factors for all-causes mortality and fatal recurrent PE 
  
 Conditions independently associated with all-cause mortality, in the whole cohort of patients, 
were age greater than 70 years (age 71-78 p=0.014, 95% CI  1.16-3.78, HR 2.09; age >78 p<0.001, 
95% CI 2.23-6.88, HR 3.92), presence of cancer (p<0.001, 95%CI  1.99-4.24, HR 2.90) and 
continuation of anticoagulant therapy (p= 0.018, 95% CI 1.13-3.65, HR 2.03) (Fig.2). All-cause 
mortality was not associated with gender (p= 0.237, 95% CI  0.87-1.77, HR 1.24), cardiovascular 
comorbidities  (p= 0.175, 95% CI  0.89-1.89, HR 1.30), previous episodes of VTE (p=0.981, 95% 
CI 0.49-2.06, HR 1.01), and unprovoked PE (p= 0.232, 95% CI 0.56-1.15, HR 0.80). Presence of 
DVT at diagnosis of PE resulted a protective factor for all-cause death (p= 0.049, 95% CI 0.42-
0.99,  HR 0.64) (Table III). 
 Fatal recurrences, in the whole cohort of patients, were significantly  associated with age greater 
than 78 years (p=0.013, 95% CI  1.76-107.50, HR 13.74), but not with gender (p=0.191, 95% CI 
0.71-5.70, HR 2.0), cardiovascular comorbidities (p= 0.432, 95% CI  0.53-4.31, HR 1.52),  
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continuation of anticoagulant therapy (p=0.873, 95% CI 0.36-3.36, HR 1.09), previous episodes of 
VTE (p= 0.938, 95% CI 0.12-6.96, HR 0.92), unprovoked PE (p= 0.194, 95% CI 0.71-5.22, HR 
1.93) and presence of DVT at diagnosis of PE (p= 0.919, 95% CI  0.39-2.85, HR 1.05). 
 
Risk factors for recurrence 
 
In the whole cohort, recurrence was significantly associated with age greater than 61 years 
(age 61-70 p=0.012, 95% CI  1.38-13.03, HR 4.24; age 71-78 p=0.015, 95% CI  1.31-12.38, HR 
4.04; age > 78 p=0.001, 95% CI  2.25-20.16, HR 6.74) and with the presence of DVT at the 
diagnosis of PE (p=0.005, 95% CI  1.29-4.19, HR 2.34). Recurrence was not associated with gender 
(p=0.073, 95% CI 0.31-1.05, HR 0.57), cardiovascular comorbidities (p=0.471, CI 95% 0.65-2.57, 
HR 1.28), cancer (p=0.389, CI 95% 0.31-1.57, HR 0.70), continuation of anticoagulant therapy 
(p=0.731, 95% CI 0.47-1.69, HR 0.89), previous episodes of VTE (p=0.499, CI 95% 0.51-3.97, HR 
1.42), unprovoked PE (p= 0.741, 95% CI 0.62-1.95, HR 1.10). (Table III). 
 
Bleeding 
 In the group of 361 patients who continued anticoagulant therapy, bleedings occurred in 21 
(5.8%) cases, of these 5 (23.8%) were classified as major bleedings and 16 (76.2%) as minor. Major 
bleedings and occurred in the 1st year in 1 case, in the 4th year in 2 cases and in the 5th year in 2 
cases and were fatal in 3 (60%) cases.  
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Table IV Table III. Risk factors for all-cause mortality and recurrence    
    
  Univariate Analysis Multivariate Analysis  
 Death 
122 
N (%) 
HR (95% ICI) p HR (95% ICI) p 
Variables      
Age 61-70 22 (18) 1.68 (0.89-3.19) 0.110   
Age 71-78 33 (27) 2.31 (1.28-4.14) 0.005 2.09 (1.16-3.78) 0.014 
Age >78 51 (41.8) 4.01 (2.31-6.94) 0.001 3.92 (2.23-6.88) 0.001 
Male gender 62 (50.8) 1.24 (0.87-1.77) 0.237   
Cancer 46 (37.7) 2.43 (1.67-3.51) 0.001 2.90 (1.99-4.24) 0.001 
Previous VTE 8 (6.5) 1.01 (0.49-2.06) 0.981   
DVT 26 (21.3) 0.53 (0.34-0.82) 0.004 0.64 (0.42-0.99) 0.049 
Cardiovascular Comorbidity 82 (67.2) 1.30 (0.89-1.89) 0.175   
Unprovoked PE  0.80 (0.56-1.15) 0.232   
Continuation of anticoagulant therapy   0.001 2.03 (1.13-3.65) 0.018 
 
      
 Recurrence 
 
47 
N (%) 
    
Variables      
Age 61-70 13 (27.7) 4.6 (1.50-14.13) 0.008 4.24 (1.38-13.03) 0.012 
Age 71-78 13 (27.7) 4.07 (1.32-12.5) 0.014 4.04 (1.31-12.38) 0.015 
Age >78 17 (36.2) 5.91 (1.98-17.60) 0.001 6.74 (2.25-20.16) 0.001 
Male gender 15 (31.9) 0.57 (0.31-1.05) 0.073   
Cancer 7 (14.9) 0.70 (0.31-1.57) 0.389   
Previous VTE 4 (8.5) 1.42 (0.51-3.97) 0.499   
DVT 24 (51.1) 2.12 (1.19-3.76) 0.010 2.34 (1.29-4.19) 0.005 
Cardiovascular Comorbidity 35 (74.5) 1.91 (0.99-3.68) 0.471   
Unprovoked PE 53 (43.4) 1.10 (0.62-1.95) 0.741   
Continuation of anticoagulant therapy 109 (89.3) 0.89 (0.47-1.69) 0.731   
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Discussion 
This prospective, observational, cohort study evaluated 5 year-outcome of consecutive 
patients with PE, who continued or stopped treatment at the end of 1 year from diagnosis, only 
according to ACCP Guide-lines [13]. To be as consistent and close to real life as possible no 
exclusion criteria were adopted.  
The first result of the present study is that the large majority of patients (almost 80%) had to 
continue anticoagulant therapy beyond the 3-6 months commonly recommended because affected 
by unprovoked PE, previous VTE, presence of active cancer, atrial fibrillation, disabling chronic 
disease. Only the remaining 20% of patients could stop prophylaxis because affected by PE 
secondary to reversible risk factors (surgery, bone fracture, immobilization, estrogen use).  To our 
knoledge, this is the first observation of such an high prevalence of patients who must continue 
prophylaxis according to Guide-lines. This curries high financial costs for public health and heavy 
burden for patients. 
The second main result is that the cumulative recurrence is about 13% in all patients and it 
does not differ significantly between patients who stop prophylaxis and those who continue for 5 
years. This, perhaps, means that prophylaxis in high risk patients such as those with unprovoked or 
recurrent PE has a protective effect even after the commonly suggested period of 3-6 months. Other 
studies report lower cumulative recurrence incidence [6, 10, 15-17]; but no study follows patients 
treated continuosly for 5 years, moreover, it is often hard to understand whether patients were or not 
under treatment during the follow-up.  
Our results also show that the risk of recurrence in the entire patients cohort examined 
increased with age (greater than 61 years), as found by others Authors too [6,10]. Also, we observed 
that the risk increased with the presence of DVT at diagnosis of PE, finding not described 
previously. In disagreement with previous studies, we found a similar risk of recurrence in both 
sexes, in unprovoked and secondary PE [4,10,18-20]; also, in contrast with previous studies we 
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found that presence of cancer was not a risk factor for recurrence [10, 21-23], and we hypothesize 
that this is likely because patients with cancer were protected by the long-term anticoagulant 
treatment. 
The specific cumulative mortality for PE was 5% in 5 years. The results are similar of those 
of other Authors [7] who report a fatal recurrence rate of 0.49-1.59 events for 100 person-years. 
Once again, the specific mortality in our data is not significantly different between patients who 
continue and those who stop prophylaxis. All-cause cumulative mortality is 29% after 5 years. Such 
a figure results similar to that reported by other Authors: 31.6% after 5 years in a paper that 
followed 1023 patients with PE [24]. In accordance with the results of other studies [7,25], the risk 
of death for fatal recurrence in the entire cohort examined increased with age (greater than 78 
years), while it did not increase with the presence of unprovoked PE, previous VTE, gender and 
presence of cancer. From our data we may also conclude that the difference in all-cause mortality is 
significantly different between the two groups of patients; indeed, patients who continue 
prophylaxis have almost 3 times greater probability of dying (RR 2.81) in respect to patients who 
stop it. A reasonable explication of this is the high prevalence of cancer among the group of patients 
who continue therapy, that apparently does not protect against the mortality due to cancer. In fact, 
our results show the presence of active cancer and advanced age (greater than 70 years) as risk 
factor for all-cause mortality. 
A third main result is that among all patients who must continue secondary prophylaxis, 
those with unprovoked or recurrent PE, show more than 3 times greater probability of dying for 
fatal recurrence than those who continue prophylaxis since affected by uncontrolled cancer or 
disabling chronic illness (RR 3.60, 95% CI 0.01-1.84). Accordingly, these data demonstrate that 
patients of the former group really have higher risk for fatal PE, while patients of the latter group 
have higher risk of dying for diseases different from recurrent fatal PE.  
Our strategy that followed current Guide-lines brought to five major bleedings (3 fatal), 
evenly distribuited in 5 years. This figure is almost as double in respect to that of other studies in 
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whom patients were not prophylaxed [26,27]. If we consider that recurrences were lower in respect 
to those reported in such studies, but the specific mortality was similar, it might be uncertain the 
utility of such strategy. However, to answer this question, other data from controlled, multicenter 
studies, should be available. 
 
Study strengthens and limitations 
 
Our study can be defined a “real life” study, in that it enrolled all consecutive patients with 
PE, without exclusion criteria. This has been possible because a Center for diagnosis and treatment 
of PE is active at the University Hospital, where all patients are uniformely followed according to a 
predefined strategy. Therefore, one strenght of our study is the inclusion of all consecutive patients 
referred to our Center, including those with cancer or other relevant comorbidities often excluded in 
other studies. According to Guide-lines, patients underwent anticoagulation for a long period of 
time, even life-long, if they showed high risk of recurrence, they stop it in the other cases. 
The adherence to Guide-lines that has allowed us to divide patients in two groups, has been 
made by adopting standardized methods for collecting baseline data and for documenting the cause 
of death. As a consequence, we could obtain long-term results in patients prophylaxed for 5 years; 
this, in our opinion, is the first demonstration of long-term outcome in such patients. Among the 
main study limitations are the fact that it is a single-centre study with a relatively small sample size. 
Another limitation would be that all our patients were treated for 1 year before starting with the 
follow-up, and this may make less comparable our data with those of studies that treat patients for 3 
or 6 months only. 
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Conclusion 
 
Our findings suggest that, according to Guide-lines, most patients (80%) should be 
anticoagulated for long periods of time, that prolonging anticoagulation markedly reduce the risk 
for fatal recurrence in patients with unprovoked PE, while it does not decrease total recurrences or 
all-cause mortality. This, indeed, is influenced greatly by the presence of cancer, both in patients 
who continue and in those who stop anticoagulant prophylaxis. Whether or not the strategy of 
adhering to Guide-lines is correct remains not demonstrated. 
 
Additional consideration 
In this study, the long-term secondary prophylaxis was made in the majority of patients by 
vitamin K antagonists. Recently, new anticoagulants (direct thrombin and direct factor Xa 
inhibitors) have been studied and investigated in a number of clinical trials (RE-SONATE, RE-
MEDY, EINSTEIN-EXTENSION, AMPLIFY_EXTENSION studies) [28-30], some of them are 
ready to be commercialized. The oral route of administration and the remarkable pharmacologic 
properties, such as the rapid onset and offset of action, the relatively short half-life, the predictable 
anticoagulant effect and the less interaction with food and drugs, make these agents easy to use and, 
thus, ideal candidates for secondary prevention of VTE, especially in patients requiring long-term 
treatment. Therefore, we cannot exclude that future Guide-lines might recommend different options, 
making our present results not applicable to different scenarios. 
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